H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on Amarin (AMRN - Research Report) today and set a price target of $3.00. The company's shares closed yesterday at $1.14.Fein covers the Healthcare sector, focusing on stocks such as Wave Life Sciences, ACADIA Pharmaceuticals, and Amarin. According to TipRanks, Fein has an average return of -12.0% and a 32.96% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Sell analyst consensus rating for Amarin with a $2.50 average price target, an 119.30% upside from current levels.
https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-hold-on-amarin-amrn-2?utm_source=advfn.com&utm_medium=referral